Mostrar el registro sencillo del ítem
Drug interactions and adverse events in a cohort of warfarin users attending public health clinics
dc.contributor.author | Colet, Christiane de Fátima | pt_BR |
dc.contributor.author | Amador, Tania Alves | pt_BR |
dc.contributor.author | Heineck, Isabela | pt_BR |
dc.date.accessioned | 2020-01-16T04:10:24Z | pt_BR |
dc.date.issued | 2019 | pt_BR |
dc.identifier.issn | 2359-4802 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/204377 | pt_BR |
dc.description.abstract | Background: Warfarin is an oral anticoagulant involved in important interactions with foods and other drugs. Objectives: To evaluate the occurrence of adverse events reported by warfarin users and their relationship with drug interactions. Methods: This was an open cohort, prospective study conducted in an 18-month period with warfarin users attending public health clinics of the city of Ijuí, Brazil. Data were collected by means of interviews administered at patients’ home every month. Patients’ responses were confirmed by review of medical records when patients sought medical care. Data were analyzed by descriptive statistics. Potential drug interactions were evaluated in a database and vitamin K consumption was quantified using a validated method. Results: A total of 68 patients were followed-up; 63 completed the study and 5 died in the study period. Mean number of medications taken by the patients was 9.6 ± 4.5, and mean number of interactions involving warfarin was 2.91 ± 1.52. Most potential interactions increased the risk of bleeding, 61 of them severe interactions and 116 moderate interactions. Eighty-seven episodes of bleeding and 4 episodes of thrombosis were reported by a total of 37 and 4 patients, respectively. At the occurrence of these events, 56.5% of warfarin users were also taking omeprazole, 35.9% were taking simvastatin and 25.0% paracetamol. Most patients had a low vitamin K intake. Conclusions: A high frequency of potential interactions between warfarin and other drugs was detected, but a low intake of foods that could possibly affect the effects of warfarin was observed. Based on our results, it seems prudent to follow patients on warfarin therapy for drug-drug interactions, aiming to control adverse effects and to promote a safe and effective therapy. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | International Journal of Cardiovascular Sciences. São Paulo (SP). Vol. 32, no. 2 (Mar./Abr. 2019), p. 110-117 | pt_BR |
dc.rights | Open Access | en |
dc.subject | Anticoagulants/adverse effects | en |
dc.subject | Farmácia | pt_BR |
dc.subject | Warfarin | en |
dc.subject | Anticoagulantes | pt_BR |
dc.subject | Varfarina | pt_BR |
dc.subject | Pharmacovigilance | en |
dc.subject | Drug interactions | en |
dc.subject | Farmacovigilância | pt_BR |
dc.subject | Interações de medicamentos | pt_BR |
dc.subject | Drug incompatibility | en |
dc.subject | Incompatibilidade de medicamentos | pt_BR |
dc.subject | Omeprazole | en |
dc.subject | Simvastatin | en |
dc.subject | Omeprazol | pt_BR |
dc.subject | Sinvastatina | pt_BR |
dc.subject | Acetaminophen | en |
dc.subject | Vitamin K | en |
dc.subject | Acetaminofen | pt_BR |
dc.subject | Delivery health care/statistics & numeral data | en |
dc.title | Drug interactions and adverse events in a cohort of warfarin users attending public health clinics | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001109107 | pt_BR |
dc.type.origin | Nacional | pt_BR |
Ficheros en el ítem
Este ítem está licenciado en la Creative Commons License
-
Artículos de Periódicos (40917)Ciencias de la Salud (10934)